HYESOOK KIM
Pharmacy in Bloomfield, MI

7695927, Apr 13, 2010

Mar 17, 2006

11/378062

Hyesook Kim - Bloomfield Hills MI, US
Jorge H. Capdevila - Nashville TN, US
Raymond R. Novak - Orchard Lake MI, US
Deanna Kroetz - Burlingame CA, US

Detroit R & D - Bloomfield Hills MI

G01N 33/53, G01N 33/531, C12Q 1/48, G01N 33/532, C07K 16/00

435 772, 435 71, 435 15, 436544, 5303898

A method to assess arachidonic acid (AA) metabolites-dependent hypertension by measuring glucuronidated dihydroxyeicosatrienoic acids (DHETs) and DHET metabolites in a biological sample which contains the epitopes unique to DHET (using any methods including GC/MS, LC/MS or ELISA) is disclosed. An example of the glucuronidated DHET metabolite is DHET-alcohols such as omega or omega-1 oxidated DHET and DHET esterified glycerol. The method further includes determining the amount of glucuronidated molecules containing a DHET-specific epitope which is immunoreactive with antibodies produced against DHETs. The present invention measuring glucuronidated DHET levels in a biological sample is useful for drug development and monitoring efficiency of drug treatment of a mammal who has AA epoxygenase-, epoxide hydrolase-and/or UDP-glucuronosyl transferase-dependent hypertension.

8409821, Apr 2, 2013

Mar 3, 2010

12/716570

Hyesook Kim - Bloomfield Hills MI, US
Jorge H. Capdevila - Nashville TN, US
Raymond F. Novak - Orchard Lake MI, US
Deanna Kroetz - San Francisco CA, US

Detroit R&D - Detroit MI

G01N 33/53, G01N 33/531, G01N 33/532, C12Q 1/48, C07K 16/00

435 772, 435 71, 435 15, 436544, 5303898

A method of assessing arachidonic acid (AA) metabolites-dependent hypertension by measuring glucuronidated dihydroxyeicosatrienoic acids (DHETs) and DHET metabolites in a biological sample which contains the epitopes unique to DHET (using any methods including GC/MS, LC/MS or ELISA). An example of the glucuronidated DHET metabolite is DHET-alcohols such as omega or omega-1 oxidated DHET and DHET esterified glycerol. The method further includes determining the amount of glucuronidated molecules containing a DHET-specific epitope which is immunoreactive with antibodies produced against DHETs.

6812212, Nov 2, 2004

Jul 26, 2001

09/915776

Hyesook Kim - Bloomfield Hills MI 48301

A61K 3800

514 18

There is provided a method of assessing oxidant stress by measuring polymerization of proteins. Also provided is a marker for oxidant stress which includes a polymerized protein. A kit for use in assessing oxidant stress, the kit including an assay for detecting polymerized proteins is also provided. A method of lowering oxidant stress by administering to a patient an effective amount of at least one reducing agent is also provided. A pharmaceutical composition for lowering oxidant stress, the pharmaceutical having an effective amount of reducing agent and a pharmaceutically acceptable carrier is also provided.

2004021, Oct 28, 2004

Feb 17, 2004

10/780339

Hyesook Kim - Bloomfield Hills MI, US
Mary Murray - Grosse Pointe MI, US
Raymond Novak - Orchard Lake MI, US

C12Q001/68, A01K067/00

800/008000, 435/004000, 435/006000

A screen for detecting, identifying, and characterizing chemicals as toxicants is based on the affect of the chemical on gene expression in animal cleavage stage embryos. A microarray screen for detecting and measuring the affects of chemicals on gene expression in animal cleavage stage embryos. A screen for detecting, identifying, and characterizing chemicals as toxicants based on the common or differential affects on gene expression in animal cleavage stage embryos and neurulation stage embryos. Markers of chemical exposure and teratogenesis identified using the screen disclosed herein. A treatment that enables the transfer of biotinylated PCR products or DNA to a membrane following gel electrophoresis by depurinating the PCR or DNA products and denaturing the PCR products or DNA.

2011026, Oct 27, 2011

Mar 3, 2011

13/039894

Hyesook Kim - Bloomfield Hills MI, US

Detroit R&D, Inc. - Detroit MI

A61K 39/395, A61P 29/00, G01N 33/574, A61P 35/00, C07K 1/00, C07K 1/14

4241391, 4241751, 4241581, 435 792, 436501

A method of producing form-specific anti-peptide antibodies for a wild type protein and its one amino acid mutated protein using a peptide antigen, by obtaining a protein sequence of the wild type protein and its one amino acid mutated protein, selecting a continuous amino acid sequence without any internal cysteine residues that includes the one amino acid mutated sequence and wild type sequence corresponding to the mutated site at the end of the sequence to obtain a synthetic mutation peptide and a synthetic wild type peptide, conjugating the synthetic peptides to a carrier protein, and immunizing an animal to produce antibodies. Methods of detecting cancer and methods of treating cancer.

2008014, Jun 19, 2008

Dec 26, 2007

11/964117

Hyesook Kim - Bloomfield Hills MI, US
Mary Murray - Grosse Pointe MI, US
Raymond F. Novak - Orchard Lake MI, US

C12Q 1/68

435 6

A screen for detecting, identifying, and characterizing chemicals as toxicants is based on the affect of the chemical on gene expression in animal cleavage stage embryos. A microarray screen for detecting and measuring the affects of chemicals on gene expression in animal cleavage stage embryos. A screen for detecting, identifying and characterizing chemicals as toxicants based on the common or differential affects on gene expression in animal cleavage stage embryos and neurulation stage embryos. Markers of chemical exposure and teratogenesis identified using the screen disclosed herein. A treatment that enables the transfer of biotinylated PCR products or DNA to a membrane following gel electrophoresis by depurinating the PCR or DNA products and denaturing the PCR products or DNA.

2008005, Mar 6, 2008

Mar 18, 2005

10/593412

Hyesook Kim - Bloomfield Hills MI, US
Alan A. Dombkowski - Canton MI, US
Raymond F. Novak - Orchard Lake MI, US
Brian B. Haab - Jenison MI, US

DETROIT R&D, INC. - Bloomfields Hills MI

C40B 30/04, C40B 40/10, C40B 50/06

506 9, 506 18, 506 26

An antibody microarray screen including a substrate, monoclonal and polyclonal antibodies that are purified immunoglobins, wherein the antibodies are spotted on predetermined positions on the substrate, and fluids unprocessed for immunoglobulin isolation (e.g., anti-sera, ascites fluids, or hybridoma culture media), wherein the unprocessed fluids are spotted on the predetermined positions on the substrate. Production of drug-metabolizing enzyme antibody microarrays containing closely related cytochromes P450 is disclosed. Methods of manufacturing an antibody microarray, an internal control molecule for use in an antibody microarray, a method of determining optimal spotting concentrations of IgG and a method to increase a detectable signal with microarray analysis are disclosed.

2004007, Apr 22, 2004

Oct 16, 2003

10/686997

Hyesook Kim - Bloomfield MI, US

G09F003/00

040/312000

An organizational system marked grid including specific locations and a spreadsheet including designations relating to the locations on the marked grid, such that each of the designations includes details regarding items located in each of the locations. A method of organizing items by placing items in a marked grid and cataloging the location of the items in a corresponding spreadsheet is also provided. A method to organize goods in a container having a grid marked on a bottom portion of the container is also provided.

5866688, Feb 2, 1999

Jun 6, 1995

8/471286

Hyesook Kim - Bloomfield Hills MI
Jonathan Charnecki - Gainsville FL
David A. Putt - Romeo MI
Edward Y. Kim - Bloomfield Hills MI

Oxford Biomedical Research, Inc. - Oxford MI

C07K 1600

5303579

A method for production of a form-specific and/or inhibitory antibody against a cytochrome P450 protein is disclosed. The method includes the steps of selecting a cytochrome P450 protein for which a form-specific and/or inhibitory antibody is needed. The amino acid sequence of the selected cytochrome P450 protein is determined and aligned with a comparison amino acid sequence using an alignment algorithm. A peptide sequence corresponding to a region of a substrate recognition site is identified and a peptide of the selected sequence prepared. Using the peptide as an immunogen, an inhibitory and/or form-specific antibody is produced.

5891622, Apr 6, 1999

Feb 24, 1998

/028543

Jason D. Morrow - Nashville TN
Hyesook Kim - Bloomfield Hills MI
L. Jackson Roberts - Nashville TN
Denis M. Callewaert - Oxford MI

Oxford Biomedical Research, Inc. - Oxford MI
Vanderbilt University - Nashville TN

C12Q 100, C12Q 126, C12Q 102

435 4

A method to assess oxidative stress in vivo by measuring the amount of free, esterified and glucuronidated forms of isoprostanes (8EPGF2) in a biological sample which contains the isoprostanes is disclosed. The method further includes determining the amount of total isoprostanes present in the sample. This amount is compared with a control sample. The oxidative stress is determined through the comparison wherein the amount of isoprostanes increase in the sample isolated from an organism undergoing oxidative stress compared to the control. Alternatively the method of the present invention provides for only the measurement of the glucuronidated form wherein the amount of glucuronidated isoprostanes increase in the sample isolated from an organism undergoing oxidative stress compared to the control.